AU2010314367A1 - Compounds inhibitors of enzyme lactate dehydrogenase (LDH) and pharmaceutical compositions containing these compounds - Google Patents

Compounds inhibitors of enzyme lactate dehydrogenase (LDH) and pharmaceutical compositions containing these compounds Download PDF

Info

Publication number
AU2010314367A1
AU2010314367A1 AU2010314367A AU2010314367A AU2010314367A1 AU 2010314367 A1 AU2010314367 A1 AU 2010314367A1 AU 2010314367 A AU2010314367 A AU 2010314367A AU 2010314367 A AU2010314367 A AU 2010314367A AU 2010314367 A1 AU2010314367 A1 AU 2010314367A1
Authority
AU
Australia
Prior art keywords
alkyl
hydroxy
carboxylic acid
phenyl
indole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2010314367A
Other languages
English (en)
Inventor
Gino Giannaccini
Carlotta Granchi
Antonio Lucacchini
Marco Macchia
Filippo Minutolo
Sarabindu Roy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universita di Pisa
Original Assignee
Universita di Pisa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universita di Pisa filed Critical Universita di Pisa
Publication of AU2010314367A1 publication Critical patent/AU2010314367A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2010314367A 2009-11-09 2010-11-05 Compounds inhibitors of enzyme lactate dehydrogenase (LDH) and pharmaceutical compositions containing these compounds Abandoned AU2010314367A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITPI2009A000140 2009-11-09
IT000140A ITPI20090140A1 (it) 2009-11-09 2009-11-09 Composto inibitore dell'enzima lattato deidrogenasi (ldh) e composizione farmaceutica che comprende tale composto
PCT/EP2010/006740 WO2011054525A1 (en) 2009-11-09 2010-11-05 Compounds inhibitors of enzyme lactate dehydrogenase (ldh) and pharmaceutical compositions containing these compounds

Publications (1)

Publication Number Publication Date
AU2010314367A1 true AU2010314367A1 (en) 2012-05-31

Family

ID=42244578

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010314367A Abandoned AU2010314367A1 (en) 2009-11-09 2010-11-05 Compounds inhibitors of enzyme lactate dehydrogenase (LDH) and pharmaceutical compositions containing these compounds

Country Status (11)

Country Link
US (1) US20120309794A1 (enExample)
EP (1) EP2499114A1 (enExample)
JP (1) JP2013510106A (enExample)
CN (1) CN102639497A (enExample)
AU (1) AU2010314367A1 (enExample)
BR (1) BR112012010868A2 (enExample)
CA (1) CA2780136A1 (enExample)
EA (1) EA201290316A1 (enExample)
IT (1) ITPI20090140A1 (enExample)
WO (1) WO2011054525A1 (enExample)
ZA (1) ZA201203993B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITPI20110143A1 (it) * 2011-12-20 2013-06-21 Univ Pisa Agenti terapeutici in grado di ridurre la produzione cellulare di acido lattico e composizioni farmaceutiche che comprendono tali composti
WO2014115764A1 (ja) * 2013-01-25 2014-07-31 国立大学法人岡山大学 乳酸脱水素酵素阻害剤およびそれを含有する医薬品
US9750761B2 (en) 2014-05-21 2017-09-05 University Of Rochester LDH inhibitors as treatment for fibrosis and fibrotic-related disorders
FR3030516B1 (fr) * 2014-12-19 2019-12-27 Galderma Research & Development Derives sulfonamides bicycles en tant qu'agonistes inverses du recepteur gamma orphelin associe aux retinoides ror gamma (t)
JP6681072B2 (ja) * 2015-02-09 2020-04-15 国立大学法人 岡山大学 乳酸脱水素酵素阻害剤およびそれを含有する抗てんかん剤
CA3029489A1 (en) * 2016-06-29 2018-01-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 1h-pyrazol-1-yl-thiazoles as inhibitors of lactate dehydrogenase and methods of use thereof
EP4306108A1 (en) * 2022-07-11 2024-01-17 Theodossis Theodossiou 5-aminolevulinic acid, or an ester thereof for use in treatment of cancer based on the inhibition of lactate dehydrogenase

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1923481A1 (de) * 1969-05-08 1970-11-12 Hoechst Ag Verfahren zur Herstellung von Amiden und Estern der 1-Hydroxy-benzimidazol-2-carbonsaeure
DE2060199A1 (de) * 1970-12-08 1972-07-06 Bayer Ag 1-Hydroxy-2-carbonamido-benzimidazol-3-oxide sowie deren Alkalisalze
GB2065098A (en) * 1979-12-07 1981-06-24 Erba Farmitalia N-substituted Thiazolyl Derivatives of 7-amino- cephalosporanic Acid
US4950602A (en) * 1987-02-20 1990-08-21 Cornell Research Foundation, Inc. Inhibition of lactate production by pyruvate adducts
US4762870A (en) * 1987-04-13 1988-08-09 The Firestone Tire & Rubber Company Rubber compositions modified with hydroxy-benz-imidazole oxides
JPH0331257A (ja) * 1989-06-28 1991-02-12 Kissei Pharmaceut Co Ltd インドール誘導体の製造方法
JPH0525140A (ja) * 1991-07-22 1993-02-02 Sankyo Co Ltd ベンズイミダゾール誘導体
US6169107B1 (en) * 1993-04-28 2001-01-02 Sumitomo Pharmaceutical Co., Ltd. Indoloylguanidine derivatives
DE69533714T2 (de) 1994-12-20 2005-03-24 Unilever N.V. Lactat-dehydrogenase Inhibitoren in kosmetischen Mitteln
JP2935102B2 (ja) * 1996-07-04 1999-08-16 大塚化学株式会社 インドール−２−カルボン酸エステル誘導体及び該誘導体を有効成分とする農園芸用殺菌剤
WO1998036774A1 (en) 1996-12-18 1998-08-27 The Johns Hopkins University School Of Medicine Method of treating a lactate dehydrogenase-a (ldh-a)-associated disorder
CA2562763A1 (en) * 2004-04-23 2006-07-20 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
WO2006017494A2 (en) 2004-08-02 2006-02-16 Elizabeth Mazzio Inhibition of anaerobic glucose metabolism
JP2009020453A (ja) * 2007-07-13 2009-01-29 Fujifilm Corp 感光性組成物、硬化性組成物、カラーフィルタ用硬化性組成物、カラーフィルタ及びその製造方法、並びに、平版印刷版原版
US8278436B2 (en) 2008-07-30 2012-10-02 Wisconsin Alumni Research Foundation Glycosylated warfarin analogs and uses thereof

Also Published As

Publication number Publication date
WO2011054525A1 (en) 2011-05-12
CA2780136A1 (en) 2011-05-12
BR112012010868A2 (pt) 2017-02-21
EA201290316A1 (ru) 2012-10-30
ITPI20090140A1 (it) 2011-05-10
CN102639497A (zh) 2012-08-15
ZA201203993B (en) 2014-11-26
EP2499114A1 (en) 2012-09-19
JP2013510106A (ja) 2013-03-21
US20120309794A1 (en) 2012-12-06

Similar Documents

Publication Publication Date Title
AU2010314367A1 (en) Compounds inhibitors of enzyme lactate dehydrogenase (LDH) and pharmaceutical compositions containing these compounds
US5958950A (en) Benzimidazole compounds useful for the treatment of inflammatory disease, atherosclerosis, restenosis or inhibiting lipoxygenase
US8119819B2 (en) Malonyl-CoA decarboxylase inhibitors useful as metabolic modulators
EP0149884B1 (en) 5-pyridyl-1,3-thiazole derivatives, their production and use
AU2004220321B2 (en) Phthalazinone derivatives
EP2891649B1 (en) Prolylhydroxylase inhibitors and methods of use
TWI280127B (en) Remedies for neurodegenerative diseases
EA011719B1 (ru) Ингибитор высвобождения воспалительного цитокина
EA008622B1 (ru) Ингибиторы ассоциированной с иммунитетом протеинкиназы
WO2013056684A2 (zh) 做为dhodh抑制剂的噻唑衍生物及其应用
EP1991536A2 (en) Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome
JP2022532718A (ja) Ａｃｓｓ２阻害剤およびその使用方法
EA010470B1 (ru) ИНГИБИТОРЫ АКТИВАЦИИ NF-kB
US9120780B2 (en) Indole or indazole derivative or salt thereof
EA019640B1 (ru) Производные индола и их применение в качестве активаторов глюкокиназы
Li et al. Synthesis and biological evaluation of 5-benzyl-3-pyridyl-1H-1, 2, 4-triazole derivatives as xanthine oxidase inhibitors
JP2004505983A (ja) ピラゾール−チアゾール化合物、これらを含む医薬組成物、およびサイクリン依存性キナーゼの阻害のためのこれらの使用方法
JP2022540560A (ja) 立体配置を有するチエノピリミジン誘導体及び薬物におけるその応用
US20080076801A1 (en) Indolylalkylpyridin-2-amines for the inhibition of beta-secretase
HK1174898A (en) Compounds inhibitors of enzyme lactate dehydrogenase (ldh) and pharmaceutical compositions containing these compounds
MXPA06000217A (es) Benzotiazol-4,7-dionas y benzoxazol-4,7-dionas con sustituyentes en la posicion 5 o 6 y procedimiento para su preparacion.
US20240376057A1 (en) 2,4-dioxo-1,2,3,4-tetrahydropyrimidine derivatives and their use in the treatment of tumors
CN108640898A (zh) 1,3-二氧六环-4,6-二酮类化合物、其制备方法、药物组合物及其应用
HK1138521B (en) Malonyl-coa decarboxylase inhibitors useful as metabolic modulators

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application